The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
A short quiz focused on the stages of multiple myeloma, including how the disease is classified and what each stage indicates. It offers a clear snapshot of how myeloma can progress and what staging means for disease management.
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Blenrep (belantamab mafodotin) in combination with other medications for hard-to-treat multiple myeloma. The…
A brief quiz highlighting the fundamentals of myeloma, from its causes and diagnosis to the areas it affects and treatment options. Designed to support learning and awareness, it offers a helpful overview of this complex blood cancer.
The European Commission has extended its approval of Johnson & Johnson’s Darzalex (daratumumab) for injection under the skin as part of a quadruple regimen…
